Multiple Myeloma Clinical Trial

PHA-739358 for the Treatment of Multiple Myeloma

Summary

The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

active multiple myeloma progressing after at least 2 prior lines of treatment
measurable disease
t(4;14) translocation
life expectancy of at least 3 months

Exclusion Criteria:

uncontrolled hypertension
myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.
pregnancy or breast feeding
active infections, including HIV

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

7

Study ID:

NCT00872300

Recruitment Status:

Terminated

Sponsor:

Nerviano Medical Sciences

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

MAYO Clinic
Scottsdale Arizona, 85259, United States
The Robert H Lurie Comprehensive Cancer Center, Northwestern University
Chicago Illinois, 60611, United States
Hôpital Huriez, Centre Hospitalier Régional Universitaire de Lille
Lille , 59037, France
University Hospital Hôtel-Dieu
Nantes , 44093, France

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

7

Study ID:

NCT00872300

Recruitment Status:

Terminated

Sponsor:


Nerviano Medical Sciences

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider